26 September 2024
Incanthera plc
("Incanthera" the "Company")
Commercial Update
Skin + CELL Initial Launch Extended Across Europe
Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology, announces an update regarding the forthcoming launch of Skin + CELL, its luxury skincare range.
On 11 July 2024, the Company announced that the initial launch of Skin + CELL would take place in approximately 60 of Marionnaud's stores in Switzerland and Austria, in September 2024, with a larger pan-European rollout to occur at a later date.
Following recent discussions and meetings with Marionnaud and AS Watson Group, the initial launch of Skin + CELL, the Company's luxury skincare brand range, is now planned to be expanded from the originally expected launch, to a broader product launch across the European retail network sooner than expected.
Marionnaud's European network totals 1,200 stores in 11 European countries.
The timing of this broader product launch is currently in discussion with Marionnaud and AS Watson Group and the Company will update the market further about this in October.
Incanthera's Skin + CELL initial launch production order, together with previously advised additional production orders, totalling 350,000 units, will now be used for the wider European roll out for anticipated orders before the Company's current financial year to 31 March 2025. This re-affirms management's projected revenues for the financial year to exceed
Alongside the significantly enhanced launch of our product range across Europe, discussions with Marionnaud and AS Watson Group also involve new product initiatives for introduction beyond this initial roll out.
We look forward to updating the market further on these details as our plans progress.
Commenting, Chairman, Tim McCarthy, said:
"Our partnership with Marionnaud and the broader AS Watson Group continues in strength, clearly demonstrated by their confidence in the broadening of the initial launch into the wider European network.
Our ongoing discussions as an exclusive supplier of luxury functional skincare within their retail network, and the potential for new product initiatives, shows the enormous opportunity in the Skin + CELL brand across the AS Watson Group."
For further information please contact:
|
Incanthera plc
Tim McCarthy, Chairman
Simon Ward, Chief Executive Officer
Suzanne Brocks, Head of Communica
|
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
|
Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner / Liam Murray / Ed Downes
|
+44 (0) 20 7213 0880 |
|
Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney |
+44 (0) 20 3650 3650/51 |
Notes to Editors
About Incanthera plc
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
About Skin + CELL
Skin + CELL is Incanthera's luxury skincare brand utilising our ground-breaking formulation and delivery expertise, to bring scientifically proven formulations to cosmetics. Skin + CELL's unique formulations, enriched with targeted bioactive B3 (an activated form of niacinamide) are other ingredients are delivered directly into the skin's cells to optimise and protect cellular health, energy and protective capabilities.
Incanthera's new bioactive skincare technology harnesses unique delivery pathways through recently patented formulations designed by our in-house experts who have previously formulated skincare for some of the world's leading skincare and pharmaceutical companies. These formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.
• Skin + CELL's unique formulations, currently enriched with targeted bioactive B3 (an activated form of niacinamide) but anticipating further bioactive ingredient formulations are delivered directly into the skin's cells to optimise cellular health, energy and protective capabilities.
• Independent studies have shown Incanthera's technology is uniquely effective in delivering Bioactive B3 into the skin, energising the living cells of the skin to maintain natural health and protection against adverse environmental challenges and maintaining even skin tones.
• Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge pharmaceutical enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.
Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.
About Marionnaud
Marionnaud is the largest luxury perfumery and cosmetics chain in Europe with over 1,220 stores and a 27% market share in France. Marionnaud is managed by the AS Watson Group based in Hong Kong, the world's largest international health and beauty retailer.
About A.S. Watson
The A.S. Watson Group is the world's largest international health and beauty retailer, with 16,100 stores in 28 markets, primarily in Asia and Europe. A member of CK Hutchison Holdings, A.S. Watson operates the world's largest portfolio of retail formats, retail brands and has the largest geographical presence including a significant online retail presence.
Forward looking statement disclaimer
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholder holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
